Belfast-based ARC Regulatory has recently secured further substantial laboratory projects with global pharmaceutical companies, providing combined revenue in excess of £3.7 million, as demand grows for its specialist clinical trial testing and laboratory services supporting precision medicine programmes.
The projects will be delivered through ARC’s in-house specialist laboratory, which provides assay validation and clinical trial sample testing for pharmaceutical, biotechnology and diagnostic companies supporting the development of novel precision medicines.
Dr David Ribeiro, Chief Operating Officer and Laboratory Director at ARC Regulatory, said: “Securing £3.7 million of additional laboratory work with global pharmaceutical companies in such a short timeframe is testament to the belief that these partners have in ARC’s ability to deliver projects efficiently and reflects the growing demand for the specialist capabilities we have built in Belfast.
READ MORE: Integrity360 partners with Chartered Accountants Ireland, safeguarding its 40,000 members globally
“Our continued investment in ARC Laboratories is creating new opportunities with a host of global clients. By combining laboratory capability with ARC’s well-recognised IVD regulatory expertise, we can provide clients with integrated support across the clinical trial lifecycle.”
The new partnerships build on continued investment by ARC’s leadership, including in its people, technology and capabilities, as the business supports a growing pipeline of global clinical trial programmes.
ARC Laboratories forms part of ARC’s wider service offering, which brings together laboratory services, specialist clinical research expertise and AI-enhanced software solutions. This integrated model enables ARC to support clients across multiple stages of the clinical trial lifecycle rather than providing laboratory testing in isolation.
The laboratory offers a growing portfolio across immunohistochemistry (IHC), ELISA and PCR, with established assays including Claudin 18, AAV9 and EGFR, and further capabilities being continuously introduced in response to client requirements.
Further specific investment in ARC’s IHC offering, including the introduction of a new Agilent IHC workflow alongside its existing Roche BenchMark platforms, has increased the range and flexibility of services available to clients.
ARC Laboratory is accredited under the CAP Laboratory Accreditation Programme and is a UKAS accredited medical laboratory to ISO 15189:2022, UKAS accreditation No. 31262. ARC Laboratory also operates as a Northern Ireland Health Institution under Article 5(5) of the EU IVDR.
Its Health Institution status provides a differentiated route for clinical trial sample testing across the UK and EU, while its accreditations provide an internationally recognised quality framework for its laboratory services.
Dr Ribeiro continued: “What differentiates ARC is that the laboratory sits within a much broader IVD-focused business. We can combine laboratory capability with our extensive regulatory expertise and our innovative digital solutions, giving clients access to more of the support they need through a single organisation.”
The latest partnerships underline the continued commercial growth of ARC Laboratories as the company expands its work with global pharmaceutical and biotechnology organisations. ARC is committed to continue investing in its laboratory capabilities and services to continue to support the growing demand from precision medicine clinical trial programmes.
Read the Summer 2026 edition free online →
Stay connected with NI's tech community:
